Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2019 Aug;94(4):321-325. doi: 10.1016/j.diagmicrobio.2019.03.003. Epub 2019 Mar 23.

2.

DTR, do we need a new definition?

Echols RM, Tillotson GS.

Clin Infect Dis. 2019 Mar 6. pii: ciz184. doi: 10.1093/cid/ciz184. [Epub ahead of print] No abstract available.

PMID:
30838418
3.

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.

Talbot GH, Das A, Cush S, Dane A, Wible M, Echols R, Torres A, Cammarata S, Rex JH, Powers JH, Fleming T, Loutit J, Hoffmann S; Foundation for the National Institutes of Health Biomarkers Consortium HABP/VABP Project Team.

J Infect Dis. 2019 Apr 19;219(10):1536-1544. doi: 10.1093/infdis/jiy578.

PMID:
30649434
4.

Cefiderocol for treatment of complicated urinary tract infections.

Portsmouth S, Echols R, Den Nagata T.

Lancet Infect Dis. 2019 Jan;19(1):23-24. doi: 10.1016/S1473-3099(18)30721-7. No abstract available.

PMID:
30587290
5.

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.

Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD.

Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25.

PMID:
30509675
6.

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.

Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF.

Int J Antimicrob Agents. 2019 Apr;53(4):456-466. doi: 10.1016/j.ijantimicag.2018.11.007. Epub 2018 Nov 22.

7.

Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model.

Stainton SM, Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01040-18. doi: 10.1128/AAC.01040-18. Print 2019 Feb.

8.

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).

Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, Sahm DF.

Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.

9.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01968-17. doi: 10.1128/AAC.01968-17. Print 2018 Feb.

10.

Characterization of Four Multidrug Resistance Plasmids Captured from the Sediments of an Urban Coastal Wetland.

Botts RT, Apffel BA, Walters CJ, Davidson KE, Echols RS, Geiger MR, Guzman VL, Haase VS, Montana MA, La Chat CA, Mielke JA, Mullen KL, Virtue CC, Brown CJ, Top EM, Cummings DE.

Front Microbiol. 2017 Oct 10;8:1922. doi: 10.3389/fmicb.2017.01922. eCollection 2017.

12.

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa.

Cai B, Echols R, Magee G, Arjona Ferreira JC, Morgan G, Ariyasu M, Sawada T, Nagata TD.

Open Forum Infect Dis. 2017 Aug 16;4(3):ofx176. doi: 10.1093/ofid/ofx176. eCollection 2017 Summer.

13.

Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.

Rex JH, Talbot GH, Goldberger MJ, Eisenstein BI, Echols RM, Tomayko JF, Dudley MN, Dane A.

Clin Infect Dis. 2017 Jul 1;65(1):141-146. doi: 10.1093/cid/cix246. Review.

14.

Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.

Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01022-17. doi: 10.1128/AAC.01022-17. Print 2017 Nov.

15.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00093-17. doi: 10.1128/AAC.00093-17. Print 2017 Sep.

16.

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.

Matsumoto S, Singley CM, Hoover J, Nakamura R, Echols R, Rittenhouse S, Tsuji M, Yamano Y.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00700-17. doi: 10.1128/AAC.00700-17. Print 2017 Sep.

17.

Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.

Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C.

J Clin Pharmacol. 2017 May;57(5):584-591. doi: 10.1002/jcph.841. Epub 2016 Nov 22.

18.

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.

Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01381-16. doi: 10.1128/AAC.01381-16. Print 2017 Jan.

19.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
21.

Targeted injection of a biocomposite material alters macrophage and fibroblast phenotype and function following myocardial infarction: relation to left ventricular remodeling.

McGarvey JR, Pettaway S, Shuman JA, Novack CP, Zellars KN, Freels PD, Echols RL Jr, Burdick JA, Gorman JH 3rd, Gorman RC, Spinale FG.

J Pharmacol Exp Ther. 2014 Sep;350(3):701-9. doi: 10.1124/jpet.114.215798. Epub 2014 Jul 14.

22.

A long and winding road; evolution of antimicrobial drug development - crisis management.

Echols RM.

Expert Rev Anti Infect Ther. 2012 Nov;10(11):1311-9. doi: 10.1586/eri.12.131. Review.

PMID:
23241188
23.

Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world.

Echols RM.

Ann N Y Acad Sci. 2011 Dec;1241:153-61. doi: 10.1111/j.1749-6632.2011.06300.x. Review.

PMID:
22191531
24.

Acute otitis media severity of symptom score in a tympanocentesis study.

Shaikh N, Wang EE, Arguedas A, Dagan R, Soley C, Song J, Echols R.

Pediatr Infect Dis J. 2011 Mar;30(3):253-5. doi: 10.1097/INF.0b013e31820662d7.

PMID:
21217538
25.

Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.

Tillotson GS, Echols RM.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S237-40. doi: 10.1086/591408. Review.

PMID:
18986296
26.

Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.

Echols RM, Tillotson GS, Song JX, Tosiello RL.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S166-75. doi: 10.1086/591399. Review.

PMID:
18986284
27.

Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel.

Stone KC, Dagan R, Arguedas A, Leibovitz E, Wang E, Echols RM, Janjic N, Critchley IA.

Antimicrob Agents Chemother. 2007 Jun;51(6):2230-5. Epub 2007 Mar 26.

28.

Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.

Hadley JA, Tillotson GS, Tosiello R, Echols RM.

Expert Rev Anti Infect Ther. 2006 Dec;4(6):923-37. Review.

PMID:
17181408
29.

Moving goalposts--regulatory oversight of antibacterial drugs.

Brenner R, Ellis-Grosse EJ, Echols R.

Nat Biotechnol. 2006 Dec;24(12):1515-20.

PMID:
17160053
30.
31.

Redefining penems.

Dalhoff A, Janjic N, Echols R.

Biochem Pharmacol. 2006 Mar 30;71(7):1085-95. Epub 2006 Jan 18. Review.

PMID:
16413506
32.

Gatifloxacin therapy for children: turn on the light.

Echols R, Hamed K, Arguedas A, Dagan R, Sher L, Sáez-Llorens X, Pichichero ME.

Clin Infect Dis. 2005 Dec 15;41(12):1824-5. No abstract available.

PMID:
16288415
33.

Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure.

Pichichero ME, Arguedas A, Dagan R, Sher L, Saez-Llorens X, Hamed K, Echols R.

Clin Infect Dis. 2005 Aug 15;41(4):470-8. Epub 2005 Jul 13. Review.

PMID:
16028153
34.

Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children.

Sher L, Arguedas A, Husseman M, Pichichero M, Hamed KA, Biswas D, Pierce P, Echols R.

Pediatr Infect Dis J. 2005 Apr;24(4):301-8.

PMID:
15818288
35.

Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children.

Sáez-Llorens X, Rodriguez A, Arguedas A, Hamed KA, Yang J, Pierce P, Echols R.

Pediatr Infect Dis J. 2005 Apr;24(4):293-300.

PMID:
15818287
36.

Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.

Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.

Antimicrob Agents Chemother. 2004 Dec;48(12):4766-77.

37.

Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study.

Leibovitz E, Piglansky L, Raiz S, Greenberg D, Hamed KA, Ledeine JM, Press J, Leiberman A, Echols RM, Pierce PF, Jacobs MR, Dagan R.

Pediatr Infect Dis J. 2003 Nov;22(11):943-9.

PMID:
14614364
38.

Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.

Drusano GL, Bilello JA, Preston SL, O'Mara E, Kaul S, Schnittman S, Echols R.

J Infect Dis. 2001 Apr 1;183(7):1126-9. Epub 2001 Mar 1.

PMID:
11237841
39.

A sequential injection cold-vapor atomic absorption method for the determination of total mercury.

Doering WE, James RR, Echols RT.

Fresenius J Anal Chem. 2000 Nov;368(5):475-9.

40.

Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis.

Echols RM, Tosiello RL, Haverstock DC, Tice AD.

Clin Infect Dis. 1999 Jul;29(1):113-9.

PMID:
10433573
41.

Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group.

Krumpe PE, Cohn S, Garreltes J, Ramirez J, Coulter H, Haverstock D, Echols R.

J Antimicrob Chemother. 1999 Mar;43 Suppl A:117-28.

PMID:
10225582
42.

Single-dose oral ciprofloxacin compared with cefotaxime and placebo for prophylaxis during transurethral surgery.

Klimberg IW, Malek GH, Cox CE, Patterson AL, Whalen E, Kowalsky SF, Echols RM.

J Antimicrob Chemother. 1999 Mar;43 Suppl A:77-84.

PMID:
10225576
43.

A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.

Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM.

J Antimicrob Chemother. 1999 Mar;43 Suppl A:67-75.

PMID:
10225575
44.

Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group.

Clifford K, Huck W, Shan M, Tosiello R, Echols RM, Heyd A.

Ann Otol Rhinol Laryngol. 1999 Apr;108(4):360-7.

PMID:
10214783
45.
46.

Ciprofloxacin versus cefuroxime axetil in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group.

Johnson PA, Rodriguez HP, Wazen JJ, Huck W, Shan M, Tosiello R, Heyd A, Echols RM.

J Otolaryngol. 1999 Feb;28(1):3-12.

PMID:
10077777
47.

Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.

Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, Graham E, Echols RM, Whalen E, Kowalsky SF.

Urology. 1998 Oct;52(4):552-8.

PMID:
9763070
48.

Ciprofloxacin versus cefuroxime axetil in the treatment of adult patients with acute bacterial sinusitis.

Klein GL, Whalen E, Echols RM, Heyd A.

J Otolaryngol. 1998 Feb;27(1):10-6.

PMID:
9511113
49.

Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.

Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA.

Pediatr Infect Dis J. 1997 Jan;16(1):112-7; discussion 123-6.

PMID:
9002120
50.

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.

Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn WA, Stevens JC, Painter BG, Thurberg BE, Haverstock DC, Perroncel RY, Echols RM.

Pediatr Infect Dis J. 1997 Jan;16(1):97-105; discussion 123-6.

PMID:
9002118

Supplemental Content

Loading ...
Support Center